Impax Laboratories (IPXL) to Release Earnings on Monday
Impax Laboratories (NASDAQ:IPXL) will be posting its Q313 quarterly earnings results on Monday, November 4th. Analysts expect Impax Laboratories to post earnings of ($0.08) per share and revenue of $110.74 million for the quarter.
Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.04 by $0.04. The company had revenue of $129.63 million for the quarter, compared to the consensus estimate of $120.75 million. During the same quarter last year, the company posted $0.60 earnings per share. Impax Laboratories’s revenue was down 22.2% compared to the same quarter last year. On average, analysts expect Impax Laboratories to post $0.38 EPS for the current fiscal year and $0.46 EPS for the next fiscal year.
Impax Laboratories (NASDAQ:IPXL) opened at 20.26 on Friday. Impax Laboratories has a 1-year low of $14.41 and a 1-year high of $27.25. The stock has a 50-day moving average of $20.35 and a 200-day moving average of $19.60. The company has a market cap of $1.356 billion and a price-to-earnings ratio of 10.27.
A number of research firms have recently commented on IPXL. Analysts at Zacks upgraded shares of Impax Laboratories from a “neutral” rating to an “outperform” rating in a research note to investors on Thursday, October 17th. They now have a $22.30 price target on the stock. On a related note, analysts at TheStreet downgraded shares of Impax Laboratories from a “buy” rating to a “hold” rating in a research note to investors on Wednesday, September 11th. Finally, analysts at Canaccord Genuity raised their price target on shares of Impax Laboratories from $20.00 to $22.00 in a research note to investors on Thursday, September 5th. They now have a “hold” rating on the stock. One analyst has rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $18.83.
Impax Laboratories Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products, referred to as generics, in addition to the development and marketing of branded products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.